Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Raj K. Maturi, MD
644
mi
from
Indianapolis, IN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Raj K. Maturi, MD
644
mi
from
Indianapolis, IN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
American Eye Institute
653
mi
from
New Albany, IN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
American Eye Institute
653
mi
from
New Albany, IN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Medical Associates Clinic, P.C.
500
mi
from
Dubuque, IA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Medical Associates Clinic, P.C.
500
mi
from
Dubuque, IA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Wolfe Eye Clinic
340
mi
from
West Des Moines, IA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Wolfe Eye Clinic
340
mi
from
West Des Moines, IA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Sabates Eye Centers Research Division
190
mi
from
Leawood, KA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Sabates Eye Centers Research Division
190
mi
from
Leawood, KA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina and Vitreous Associates of Kentucky
725
mi
from
Lexington, KY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina and Vitreous Associates of Kentucky
725
mi
from
Lexington, KY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Paducah Retinal Center
508
mi
from
Paducah, KY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Paducah Retinal Center
508
mi
from
Paducah, KY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Elman Retina Group, PA
1154
mi
from
Baltimore, MD
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Elman Retina Group, PA
1154
mi
from
Baltimore, MD
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Wilmer Eye Institute at Johns Hopkins
1148
mi
from
Baltimore, MD
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Wilmer Eye Institute at Johns Hopkins
1148
mi
from
Baltimore, MD
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Consultants of Delmarva, P.A.
1206
mi
from
Salisbury, MD
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Consultants of Delmarva, P.A.
1206
mi
from
Salisbury, MD
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Joslin Diabetes Center
1444
mi
from
Boston, MA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Joslin Diabetes Center
1444
mi
from
Boston, MA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Henry Ford Health System, Dept of Ophthalmology and Eye Care Services
841
mi
from
Detroit, MI
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Henry Ford Health System, Dept of Ophthalmology and Eye Care Services
841
mi
from
Detroit, MI
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Vitreo-Retinal Associates
737
mi
from
Grand Rapids, MI
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Vitreo-Retinal Associates
737
mi
from
Grand Rapids, MI
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
The Retina Center
551
mi
from
Minneapolis, MN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
The Retina Center
551
mi
from
Minneapolis, MN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Barnes Retina Institute
414
mi
from
St. Louis, MO
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Barnes Retina Institute
414
mi
from
St. Louis, MO
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Delaware Valley Retina Associates
1248
mi
from
Lawrence Twp, NJ
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Delaware Valley Retina Associates
1248
mi
from
Lawrence Twp, NJ
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
The New York Eye and Ear Infirmary/Faculty Eye Practice
1286
mi
from
New York, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
The New York Eye and Ear Infirmary/Faculty Eye Practice
1286
mi
from
New York, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Mount Sinai School of Medicine, Dept. of Ophthalmology
1286
mi
from
New York, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Mount Sinai School of Medicine, Dept. of Ophthalmology
1286
mi
from
New York, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Consultants of Western New York
1061
mi
from
Orchard Park, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Consultants of Western New York
1061
mi
from
Orchard Park, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Eye Care for the Adirondacks
1347
mi
from
Plattsburgh, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Eye Care for the Adirondacks
1347
mi
from
Plattsburgh, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina-Vitreous Surgeons of Central New York, PC
1193
mi
from
Syracuse, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina-Vitreous Surgeons of Central New York, PC
1193
mi
from
Syracuse, NY
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
University of North Carolina, Dept of Ophthalmology
1043
mi
from
Chapel Hill, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
University of North Carolina, Dept of Ophthalmology
1043
mi
from
Chapel Hill, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Charlotte Eye Ear Nose and Throat Assoc, PA
958
mi
from
Charlotte, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Charlotte Eye Ear Nose and Throat Assoc, PA
958
mi
from
Charlotte, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Piedmont Retina Specialists, PA
1001
mi
from
Greensboro, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Piedmont Retina Specialists, PA
1001
mi
from
Greensboro, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Mid-America Retina Consultants, P.A.
1009
mi
from
Kansas City, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Mid-America Retina Consultants, P.A.
1009
mi
from
Kansas City, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Wake Forest University Eye Center
979
mi
from
Winston Salem, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Wake Forest University Eye Center
979
mi
from
Winston Salem, NC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Associates of Cleveland, Inc.
904
mi
from
Beachwood, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Associates of Cleveland, Inc.
904
mi
from
Beachwood, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Case Western Reserve Univ
899
mi
from
Cleveland, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
899
mi
from
Cleveland, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
OSU Eye Physicians and Surgeons, LLC.
810
mi
from
Columbus, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
OSU Eye Physicians and Surgeons, LLC.
810
mi
from
Columbus, OH
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Northwest, PC
1383
mi
from
Portland, OR
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Northwest, PC
1383
mi
from
Portland, OR
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Family Eye Group
1163
mi
from
Lancaster, PA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Family Eye Group
1163
mi
from
Lancaster, PA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
University of Pennsylvania Scheie Eye Institute
1225
mi
from
Philadelphia, PA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
University of Pennsylvania Scheie Eye Institute
1225
mi
from
Philadelphia, PA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Carolina Retina Center
972
mi
from
Columbia, SC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Carolina Retina Center
972
mi
from
Columbia, SC
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Southeastern Retina Associates, PC
843
mi
from
Kingsport, TN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Southeastern Retina Associates, PC
843
mi
from
Kingsport, TN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Southeastern Retina Associates, P.C.
777
mi
from
Knoxville, TN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Southeastern Retina Associates, P.C.
777
mi
from
Knoxville, TN
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
West Texas Retina Consultants P.A.
382
mi
from
Abilene, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
West Texas Retina Consultants P.A.
382
mi
from
Abilene, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Research Center
515
mi
from
Austin, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Research Center
515
mi
from
Austin, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina and Vitreous of Texas
569
mi
from
Houston, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina and Vitreous of Texas
569
mi
from
Houston, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Baylor Eye Physicians and Surgeons
569
mi
from
Houston, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Baylor Eye Physicians and Surgeons
569
mi
from
Houston, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Texas Retina Associates
342
mi
from
Dallas, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Texas Retina Associates
342
mi
from
Dallas, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Valley Retina Institute
797
mi
from
Harlingen, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Valley Retina Institute
797
mi
from
Harlingen, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retinal Consultants of San Antonio
576
mi
from
San Antonio, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retinal Consultants of San Antonio
576
mi
from
San Antonio, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Medical Center Ophthalmology Associates
576
mi
from
San Antonio, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Medical Center Ophthalmology Associates
576
mi
from
San Antonio, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Virginia Retina Center
1098
mi
from
Leesburg, VA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Virginia Retina Center
1098
mi
from
Leesburg, VA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
University of Washington Medical Center
1410
mi
from
Seattle, WA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
University of Washington Medical Center
1410
mi
from
Seattle, WA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Medical College of Wiconsin
630
mi
from
Milwaukee, WI
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Medical College of Wiconsin
630
mi
from
Milwaukee, WI
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Status: Archived
Covance Clinical Research Unit, Inc.
1128
mi
from
Daytona Beach, FL
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Status: Archived
Updated: 1/1/1970
Covance Clinical Research Unit, Inc.
1128
mi
from
Daytona Beach, FL
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Status: Archived
Covance Clinical Research Unit, Inc.
3717
mi
from
Honolulu, HI
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Status: Archived
Updated: 1/1/1970
Covance Clinical Research Unit, Inc.
3717
mi
from
Honolulu, HI
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Status: Archived
Covance Clinical Research Unit
512
mi
from
Austin, TX
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Status: Archived
Updated: 1/1/1970
Covance Clinical Research Unit
512
mi
from
Austin, TX
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Status: Archived
Covance Clinical Research Unit, Inc.
344
mi
from
Dallas, TX
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Status: Archived
Updated: 1/1/1970
Covance Clinical Research Unit, Inc.
344
mi
from
Dallas, TX